Mi SciELO
Servicios personalizadosServicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Farmacia Hospitalaria
versión On-line ISSN 2171-8695versión impresa ISSN 1130-6343
Resumen
FERNANDEZ-CANABATE, Eva y FERNANDEZ-CANABATE, Sonia. Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin’s lymphoma. Farm Hosp. [online]. 2018, vol.42, n.1, pp.20-21. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.10830.
Clinical case:
A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were administered. 12 months after the last intravitreal rituximab dose, signs and symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab administration were not observed.
Discussion:
Intravitreal rituximab is an effective and safe treatment of intravitreal lymphoma, by inducing complete remission; it could be a good alternative to other therapeutic options with greater number of serious complications.
Palabras clave : Rituximab; Primary colon lymphoma; Diffuse large B cell lymphoma; Vitreoretinal lymphoma; Intravitreal injection; Non Hodgkin’s lymphoma.
